Lawendy Bishoy, Adekunle Ayooluwatomiwa, Rubens Muni, Babajide Oyedotun, Sedarous Mary, Tariq Tahniyat, Okafor Philip
Department of Internal Medicine, University of Western Ontario, London, CAN.
Department of Gastroenterology, Washington University School of Medicine, St. Louis, USA.
Cureus. 2024 Aug 15;16(8):e66931. doi: 10.7759/cureus.66931. eCollection 2024 Aug.
Background The impact of the coronavirus disease-2019 (COVID-19) pandemic on patients with acute gastrointestinal (GI) presentations including acute pancreatitis, diverticulitis, and GI bleeding, requiring hospitalization, has not been fully characterized at the population level in the United States. Aims We used the National Inpatient Sample to describe inpatient gastroenterology outcomes in the United States during the first year of the pandemic (2020), using 2018 and 2019 as comparator years. Methods Using the National Inpatient Sample, we explored year-to-year and month-to-month trends in hospitalizations, length of stay, and inpatient mortality for GI presentations, including luminal, biliary, infectious, inflammatory, and pancreatic diseases, with regression modeling. Relative change was used to compare time periods. Results We observed significantly lower rates of hospitalization for most acute GI conditions in 2020 relative to 2019. Despite this, we noted an increase in all-cause mortality (0.9% in 2019 and 1.1% in 2020, p<0.001) and hospital costs for patients hospitalized with acute presentations of GI-related conditions in 2020 relative to 2019. Importantly, we also observed increased mortality among COVID-19-positive patients who were hospitalized for acute pancreatitis (OR 2.56; 95% CI 1.37-6.53), variceal upper GI bleeding (OR 2.88; 95% CI 1.29-3.84), ulcerative colitis (OR 4.50; 95% CI 1.14-7.74), and acute cholangitis (OR 2.43; 95% CI 1.14-4.93). In 2020, the lowest number of admissions for all conditions occurred in April, coinciding with lockdowns ordered by most state governments. Conclusions Acute GI-related hospitalizations, in general, decreased in 2020 but this was associated with higher hospital costs and all-cause mortality increased compared with the pre-pandemic period.
2019年冠状病毒病(COVID-19)大流行对包括急性胰腺炎、憩室炎和胃肠道出血等需要住院治疗的急性胃肠道(GI)疾病患者的影响,在美国人群层面尚未得到充分描述。目的:我们使用全国住院患者样本,以2018年和2019年作为对照年份,描述美国在大流行第一年(2020年)的住院胃肠病学结局。方法:使用全国住院患者样本,我们通过回归建模探索了胃肠道疾病(包括腔内、胆道、感染性、炎症性和胰腺疾病)住院人数、住院时间和住院死亡率的逐年和逐月趋势。使用相对变化来比较不同时间段。结果:我们观察到,与2019年相比,2020年大多数急性胃肠道疾病的住院率显著降低。尽管如此,我们注意到2020年因急性胃肠道相关疾病住院患者的全因死亡率有所增加(2019年为0.9%,2020年为1.1%,p<0.001),且住院费用增加。重要的是,我们还观察到因急性胰腺炎住院的COVID-19阳性患者(比值比2.56;95%置信区间1.37 - 6.53)、静脉曲张性上消化道出血患者(比值比2.88;95%置信区间1.29 - 3.84)、溃疡性结肠炎患者(比值比4.50;95%置信区间1.14 - 7.74)和急性胆管炎患者(比值比2.43;95%置信区间1.14 - 4.93)的死亡率增加。2020年,所有疾病的入院人数最低值出现在4月,与大多数州政府下令的封锁时间一致。结论:总体而言,2020年急性胃肠道相关住院人数减少,但这与更高的住院费用相关,且与大流行前相比全因死亡率增加。